|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 7/29/20 OncoCyte Corp 10-Q 6/30/20 76:9.6M M2 Compliance/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 356K
2: EX-3.1 Articles of Incorporation/Organization or Bylaws HTML 44K
3: EX-10.1 Material Contract HTML 31K
4: EX-31 Certification -- §302 - SOA'02 HTML 36K
5: EX-32 Certification -- §906 - SOA'02 HTML 25K
12: R1 Document and Entity Information HTML 53K
13: R2 Condensed Consolidated Balance Sheets HTML 114K
14: R3 Condensed Consolidated Balance Sheets HTML 40K
(Parenthetical)
15: R4 Condensed Consolidated Statements of Operations HTML 81K
(Unaudited)
16: R5 Condensed Consolidated Statements of Comprehensive HTML 40K
Loss (Unaudited)
17: R6 Condensed Consolidated Statements of Cash Flows HTML 126K
(Unaudited)
18: R7 Organization, Description of the Business and HTML 36K
Liquidity
19: R8 Basis of Presentation and Summary of Significant HTML 72K
Accounting Policies
20: R9 Selected Balance Sheet Components HTML 45K
21: R10 Right-Of-Use Assets, Machinery and Equipment, Net HTML 31K
22: R11 Acquisition of Insight HTML 70K
23: R12 Goodwill and Intangible Assets, Net HTML 32K
24: R13 Equity Method Investment in Razor Genomics, Inc. HTML 44K
25: R14 Related Party Transactions HTML 35K
26: R15 Loan Payable to Silicon Valley Bank HTML 36K
27: R16 Shareholders' Equity HTML 68K
28: R17 Stock-Based Compensation HTML 56K
29: R18 Income Taxes HTML 31K
30: R19 Commitments and Contingencies HTML 60K
31: R20 Basis of Presentation and Summary of Significant HTML 111K
Accounting Policies (Policies)
32: R21 Basis of Presentation and Summary of Significant HTML 29K
Accounting Policies (Tables)
33: R22 Selected Balance Sheet Components (Tables) HTML 49K
34: R23 Right-Of-Use Assets, Machinery and Equipment, Net HTML 29K
(Tables)
35: R24 Acquisition of Insight (Tables) HTML 53K
36: R25 Goodwill and Intangible Assets, Net (Tables) HTML 32K
37: R26 Equity Method Investment in Razor Genomics, Inc. HTML 30K
(Tables)
38: R27 Related Party Transactions (Tables) HTML 28K
39: R28 Shareholders' Equity (Tables) HTML 63K
40: R29 Stock-Based Compensation (Tables) HTML 61K
41: R30 Commitments and Contingencies (Tables) HTML 48K
42: R31 Organization, Description of the Business and HTML 36K
Liquidity (Details Narrative)
43: R32 Basis of Presentation and Summary of Significant HTML 51K
Accounting Policies (Details Narrative)
44: R33 Basis of Presentation and Summary of Significant HTML 31K
Accounting Policies - Common Stock Equivalents
Excluded from Computation of Diluted Net Loss Per
Share of Common Stock (Details)
45: R34 Selected Balance Sheet Components - Schedule of HTML 32K
Reconciliation of Cash, Cash Equivalents, and
Restricted Cash (Details)
46: R35 Selected Balance Sheet Components - Schedule of HTML 32K
Prepaid Expenses and Other Current Assets
(Details)
47: R36 Selected Balance Sheet Components - Schedule of HTML 31K
Deposits and Other Noncurrent Assets (Details)
48: R37 Selected Balance Sheet Components - Schedule of HTML 34K
Accrued Expenses and Other Current Liabilities
(Details)
49: R38 Right-Of-Use Assets, Machinery and Equipment, Net HTML 28K
(Details Narrative)
50: R39 Right-Of-Use Assets, Machinery and Equipment, Net HTML 34K
- Schedule of Right of Use Assets, Machinery and
Equipment, Net (Details)
51: R40 Acquisition of Insight (Details Narrative) HTML 77K
52: R41 Acquisition of Insight - Schedule of Fair Value of HTML 36K
Aggregate Merger Consideration (Details)
53: R42 Acquisition of Insight - Schedule of Fair Value of HTML 29K
Aggregate Merger Consideration (Details)
(Parenthetical)
54: R43 Acquisition of Insight - Schedule of Intangible HTML 58K
Assets Acquired and Liabilities Assumed (Details)
55: R44 Acquisition of Insight - Schedule of Identifiable HTML 29K
Intangible Assets and Estimated Useful Life
(Details)
56: R45 Acquisition of Insight - Schedule of Fair Value of HTML 37K
Contingent Consideration Liability (Details)
57: R46 Goodwill and Intangible Assets, Net - Schedule of HTML 38K
Goodwill and Intangible Assets (Details)
58: R47 Equity Method Investment in Razor Genomics, Inc. HTML 79K
(Details Narrative)
59: R48 Equity Method Investment in Razor Genomics, Inc. - HTML 43K
Schedule of Condensed Statement of Operations
(Details)
60: R49 Related Party Transactions (Details Narrative) HTML 44K
61: R50 Related Party Transactions - Schedule of Aggregate HTML 35K
Use of Fees Charged (Details)
62: R51 Loan Payable to Silicon Valley Bank (Details HTML 97K
Narrative)
63: R52 Shareholders' Equity (Details Narrative) HTML 49K
64: R53 Shareholders' Equity - Schedule of Components of HTML 78K
Shareholder's Equity (Details)
65: R54 Stock-Based Compensation (Details Narrative) HTML 49K
66: R55 Stock-Based Compensation - Summary of Stock Option HTML 90K
Activity (Details)
67: R56 Stock-Based Compensation - Summary of Stock-based HTML 32K
Compensation Expense (Details)
68: R57 Stock-Based Compensation - Schedule of Assumptions HTML 33K
Used to Calculate Fair Value of Stock Options
(Details)
69: R58 Income Taxes (Details Narrative) HTML 25K
70: R59 Commitments and Contingencies (Details Narrative) HTML 58K
71: R60 Commitments and Contingencies - Schedule of HTML 30K
Supplemental Cash Flow Information Related to
Operating and Financing Lease (Details)
72: R61 Commitments and Contingencies - Schedule of HTML 54K
Supplemental Balance Sheet Information Related to
Operating and Financing Leases (Details)
73: R62 Commitments and Contingencies - Schedule of Future HTML 72K
Minimum Lease Commitments for Operating and
Financing Leases (Details)
75: XML IDEA XML File -- Filing Summary XML 142K
74: EXCEL IDEA Workbook of Financial Reports XLSX 114K
6: EX-101.INS XBRL Instance -- ocx-20200630 XML 1.35M
8: EX-101.CAL XBRL Calculations -- ocx-20200630_cal XML 212K
9: EX-101.DEF XBRL Definitions -- ocx-20200630_def XML 535K
10: EX-101.LAB XBRL Labels -- ocx-20200630_lab XML 1.12M
11: EX-101.PRE XBRL Presentations -- ocx-20200630_pre XML 798K
7: EX-101.SCH XBRL Schema -- ocx-20200630 XSD 206K
76: ZIP XBRL Zipped Folder -- 0001493152-20-014178-xbrl Zip 166K
Exhibit 10.1
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
C:
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/12/23 Oncocyte Corp. 10-K 12/31/22 94:11M M2 Compliance LLC/FA 5/02/22 Oncocyte Corp. 10-K/A 12/31/21 12:649K M2 Compliance LLC/FA 3/11/22 Oncocyte Corp. 10-K 12/31/21 90:10M M2 Compliance LLC/FA 5/28/21 OncoCyte Corp. S-3 3:345K M2 Compliance LLC/FA 5/17/21 OncoCyte Corp. 10-Q 3/31/21 85:5.1M M2 Compliance LLC/FA 4/30/21 OncoCyte Corp. 10-K/A 12/31/20 2:488K M2 Compliance LLC/FA 3/19/21 OncoCyte Corp. 10-K 12/31/20 93:7.4M M2 Compliance LLC/FA 11/12/20 OncoCyte Corp. 10-Q 9/30/20 84:5.2M M2 Compliance LLC/FA |